|
Issues (Archived 11/13/2009)
Fourth Annual Philip S. Chen, Jr., Ph.D. Distinguished Lecture on Innovation and Technology Transfer
The Office of the Director, NIH, invites you to the fourth annual Philip S. Chen, Jr., Ph.D. Distinguished Lecture on Innovation and Technology Transfer. The lecture will be held on Friday, November 13, 2009, at 10:00 AM in the Masur Auditorium, Building 10, NIH campus in Bethesda, Maryland.
Drs. Harvey Alter and Robert Purcell will present "Viral Hepatitis and the NIH: A Jaundiced View of History." Dr. Alter is the Chief, Infectious Disease, Department of Transfusion Medicine, in the NIH Clinical Research Center. Dr. Purcell is the Co-chief, Laboratory of Infectious Diseases in the National Institute of Allergy and Infectious Diseases.
For more information, please contact Craig Woodside at 301-496-0472 or woodsidec@od.nih.gov. For sign language interpretation or accommodation for disabilities, please contact Sharon Fields at 301-594-7700 or fieldssh@mail.nih.gov.
Issues (Archived 11/03/2009)
New University Training Program to Aid Commercialization of NIH Research Discoveries
The U.S. National Science Foundation through its Partnerships for Innovation program has awarded a grant to the University of Maryland, Baltimore County (UMBC) to establish an “ACTiVATE® at NIH” program to train post-doctoral research fellows who have completed their studies at the National Institutes of Health and other federal labs in the region to start technology-based companies.
Based upon the successful ACTiVATE® program at UMBC, which trains mid-career women to start companies using technologies developed at area universities and research institutions, ACTiVATE® at NIH will provide postdocs (both men and women) beginning in early 2010 with the training and support needed to help start new companies or to pursue an entrepreneurial career path. ACTiVATE® at NIH will recruit both postdocs and individuals from the business community as participants so they can form interdisciplinary teams to pursue opportunities for start-up companies.
Through a partnership with the NIH Office of Technology Transfer, participants will have the opportunity to evaluate technologies from NIH and other federal labs as part of the program. Other program partners include Rockville Economic Development, Inc. (REDI), Montgomery College, Human Workflows LLC, Montgomery County Department of Economic Development and The Johns Hopkins University Carey School of Business. Further details about the ACTiVATE® programs can be found here.
Issues (Archived 10/07/2009)
NIH and NIST Bio-Imaging Technologies to be Featured at an Upcoming TEDCO Technology Transfer and Commercialization Showcase
Please join us on Tuesday, October 6, 2009 at the National Institute of Standards and Technology (NIST) campus in Gaithersburg, Maryland for an opportunity to learn about the latest discoveries in the field of bio-imaging from the NIH and NIST laboratories.
This Showcase will include brief presentations highlighting these technologies, poster sessions, and an opportunity to tour NIST facilities.
For a brief overview of the Showcase click here.
Detailed information about this Showcase, including registration and agenda, is available at the TEDCO website: http://www.marylandtedco.org/calendarofevents/detail.cfm?eventid=271.
Issues (Archived 8/07/2009)
GAO ISSUES ITS REPORT ON “Information on the Government’s Right to Assert Ownership Control over Federally Funded Inventions”
The Bayh-Dole Act which was enacted in 1980, in part, to address the low utilization rate of federal patents and to assist in the U.S. competitiveness. The Act provides the Government with certain rights to protect the public against the nonuse or unreasonable use of federally funded inventions. One of these rights, known as the “march-in” authority, authorizes federal agencies, including NIH, to require the contractor or grantee or licensee to grant a license to any responsible entity or entities when credible information exists that certain statutory conditions in the Bayh-Dole Act have not been met. The GAO on July 27, 2009 issued its report on its eight month study of the use by Federal agencies (NIH, DOD, DOE, and NASA) of the Bayh-Dole “march-in” authority. The report can be found at http://www.ott.nih.gov/PDFs/GAOreportTT.pdf.
Issues (Archived 7/28/2009)
Cooperative Research & Development Agreements from the National Institutes of Health Featured In Licensing Executives Society International Journal Series
Cooperative Research Development Agreements (CRADAs) from the National Institutes of Health (NIH) and the Department of Energy are the focus of a new series of articles published in les Nouvelles, the Journal of the Licensing Executive Society International (LESI). A two part series entitled “Intellectual Property and Other Issues in Cooperative Research and Development Agreements (CRADAs)” appears in the March and June issues of the journal published by LESI, an association of 32 national and regional societies who are engaged in the profession of licensing and other aspects of transferring or developing intellectual property.
Co-authored by Matthew W. Sagal, Senior Manager of the Alliance Management Group, Gene Slowinski, Director of Strategic Alliance Research at Rutgers University, Kenneth B. Freese, Manager of Intellectual Asset Strategies at the Los Alamos National Laboratories and Steven M. Ferguson, Deputy Director of Licensing & Entrepreneurship at the NIH Office of Technology Transfer, the article series highlights patent licensing for new inventions arising from CRADA collaborations between companies and these two federal laboratories. Individual CRADA licensing case studies such as “Alliance for Advanced Energy Solutions” (Los Alamos) and “Developing Velcade® for Treatment of Multiple Myeloma” (NIH) are also included.
Interested parties can read the March issue, the June issue or obtain specific information about starting their own CRADA collaboration with at NIH here.
Issues (Archived 6/04/2009)
Announcement: Public Teleconference with Dr. Yves Pommier of the National Cancer Institute to discuss azatoxins, a novel class of anticancer compounds
Among his many notable scientific contributions, Dr. Pommier established topoisomerase enzymes as exceptional targets for anticancer drugs. Currently available topoisomerase inhibitors are effective chemotherapeutics, but have several disadvantages. With the goal of creating improved anticancer drugs, Dr. Yves Pommier at the National Cancer Institute developed a new class of chemotherapeutic agents named azatoxins that act by inhibiting the function of the topoisomerase II (top2) family of enzymes and the polymerization of tubulin. Laboratory experiments using the NCI-60 tumor cell panel have established that azatoxins are effective against disseminated leukemia and localized tumors, such as non-small cell lung and colon cancer. In comparison to etoposide, a top2 inhibitor commonly used in chemotherapy, certain azatoxin derivatives show 100 times greater anticancer activity. Indeed, azatoxins have the potential to be developed into chemotherapeutics that outperform currently utilized top2 inhibitors.
During this public teleconference, Dr. Pommier will briefly describe the results supporting the development of azatoxins as anticancer drugs. Subsequently, Dr. Pommier will be available to answer questions related to this technology.
Licensing and collaborative research opportunities will also be discussed.
Additional details were published in the Federal Register on Thursday, April 23, 2009 [74 FR 18585-18586]
Date and Time: Thursday, June 4, 2009 at 1:30 PM (EST)
Contact: If you are interested in participating in this teleconference, please contact Samuel Bish, Ph.D. (Email: bishse@mail.nih.gov; Phone: 301-435-5282) for details and call-in instructions.
Issues (Archived 5/27/2009)
Announcement: Public Teleconference with Dr. Jeffrey Schlom of the National Cancer Institute to discuss collaborative research opportunities related to TRICOM, a clinically-proven cancer vaccine technology
Dr. Schlom leads the Laboratory of Tumor Immunology and Biology at NCI where his laboratory carries out translational research focusing on the development of new immunotherapies and immunologic strategies for cancer treatment and prevention. A major breakthrough from his research is the development of TRICOM, a synergistic triad of costimulatory molecules used in cancer vaccines for the prevention and treatment of cancer. TRICOM together with tumor-associated antigens (TAAs) can be used to enhance the immune response against cancer cells and therefore, can serve as vaccines for specific cancers. Additionally, Dr. Schlom has identified several agonist epitope peptides within weakly antigenic TAAs and novel target antigens that can be used with TRICOM to trigger an immune response against a range of cancers. Already multiple clinical studies support that TRICOM is safe and is effective and with further development it has the potential for revolutionizing the treatment and prevention of cancer.
During this public teleconference, Dr. Schlom will give a brief presentation of the technology and clinical results supporting the use of TRICOM in the development of cancer vaccines. Subsequently, Dr. Schlom will be available to answer questions related to this subject.
Licensing opportunities will also be discussed.
Additional details were published in the Federal Register on Wednesday, May 6, 2009 [74 FR 20961-20962]
Date and Time: Wednesday, May 27, 2009 at 2:00 PM (EST)
Contact: If you are interested in participating in this teleconference, please contact Sabarni Chatterjee, Ph.D. (Email: chatterjeesa@mail.nih.gov; Phone: 301-435-5587) for details and call-in instructions.
Archived Issues..
Issues (Archived 4/29/2009)
Encouraging Results for Prostate Cancer Vaccine Released
Dr. Jeffrey Schlom, Chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute, National Institutes of Health (NIH), led the scientific team that developed PROSTVAC, a prostate cancer vaccine technology. PROSTVAC is currently Bavarian Nordic’s (BN) lead prostate cancer vaccine candidate. Bavarian Nordic Immunotherapeutics (BNIT, U.S. subsidiary of BN) has a license from the NIH to further develop the vaccine. BN recently released encouraging clinical data for the vaccine at the Genitourinary Cancers Symposium (GU) on February 26-28, 2009 in Orlando, Florida. This announcement is the first among several other study results that are expected to be released in 2009. For further details, please read the Press Release from BN.
Issues (Archived 3/20/2009)
OTT Career Opportunity
The NIH Office of Technology Transfer is seeking a qualified individual to fill a key Technology Licensing Specialist vacancy. The ideal candidate will possess knowledge and experience in technology transfer related activities, such as intellectual property management, evaluation of its commercial potential, and development/execution of intellectual property agreements.
A link to the detailed notice, posted at USAJOBS, may be found on our Career Opportunities webpage.
Issues (Archived 3/04/2009)
OTT Launches the Product Showcase on Its Website
OTT is proud to announce that it has launched the Product Showcase!
The NIH Intramural Research Program has invented numerous technologies that were licensed to companies for commercial development and now are on the market. Products showcased on the site are utilized every day to detect, treat or prevent disease or assist researchers as they continue to explore ways to develop newer and more effective health care products and procedures.
The Showcase currently includes 35 products out of over 400 products that could be highlighted. Some products in the Showcase are FDA-approved and some do not necessitate FDA approval, but all have made important contributions to public health or the advancement of science.
Additional product images and features, such as enhanced sorting and filtering, will be added over time.
We hope you will find this Showcase illuminating about the vital role the NIH Intramural Research Program has played in the effort to advance significantly our capacity to protect and improve health.
Issues (Archived 2/05/2009)
Eleven OTT Staff Members Receive Technology Transfer Instructional Awards
The Foundation for Advanced Education in the Sciences (FAES) has given "2008 Team Teaching Awards" to Office of Technology Transfer (OTT) staff members Sue Ano, Mojdeh Bahar, Steven Ferguson, Bruce Goldstein, George Keller, Ajoy Prabhu, Uri Reichman, Richard Rodriguez, Mark Rohrbaugh, David Sadowski and Jeff Walenta for volunteering their time to organize and conduct evening training programs in technology transfer during FY’08 for the local community. The courses were conducted through the FAES Graduate School at NIH as part of its new educational "Certificate in Technology Transfer Program". As a result of these efforts, more than 100 persons received various semester-long training courses in technology transfer . Many individuals who have received such training have been hired into the field by NIH, other government agencies, as well as university or corporate programs in biomedical technology transfer. Further details about the Certificate in Technology Transfer Program and upcoming technology transfer course offerings at NIH facilities can be found through the FAES Graduate School. The FAES is an independent foundation at NIH organized to foster scientific research and education by facilitating communication among scientists and by sponsoring formal instruction in the sciences and related educational activities.
Archived Issues..
|